These studies indicate that IL-23 is important in maintaining tumorigenic capacity of ovarian CSLCs and pharmacological targeting of IL-23 signaling may be beneficial for the treatment of ovarian cancer in a clinical setting. This evidence concerns the gene IL37 and ovarian cancer.